LK21-01g

Main Content

Utility of pre-transplant flow cytometry tests of measurable residual disease in AML in first remission: CIBMTR analysis

Study #: LK21-01g

Study Status: Published

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in Acute Myeloid Leukemia in first complete remission: CIBMTR analysis.

Citation

Tettero JM, Zhang MJ, Liu W, Nawas MT, Milano F, Bejanyan N, Bachanova V, Broglie L, Saber W, Gui G, Dillon LW, Walter RB, Page KM, Hourigan CS, El Chaer F.

Haematologica. 2026, May 28: (): . doi: 10.3324/haematol.2026.300764. Epub 2026, May 28. PMCID:.

PubMed

PMID: 42206435

Abstract